AU2020258017B2 - New pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling - Google Patents

New pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling Download PDF

Info

Publication number
AU2020258017B2
AU2020258017B2 AU2020258017A AU2020258017A AU2020258017B2 AU 2020258017 B2 AU2020258017 B2 AU 2020258017B2 AU 2020258017 A AU2020258017 A AU 2020258017A AU 2020258017 A AU2020258017 A AU 2020258017A AU 2020258017 B2 AU2020258017 B2 AU 2020258017B2
Authority
AU
Australia
Prior art keywords
difluorophenyl
cyclopropyl
amine
sch
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020258017A
Other languages
English (en)
Other versions
AU2020258017A1 (en
Inventor
Eric Goffin
Nicolas Jacques
Patrizio LANCELLOTTI
Lucia MUSUMECI
Cécile OURY
Bernard Pirotte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liège
Original Assignee
University of Liège
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Liège filed Critical University of Liège
Publication of AU2020258017A1 publication Critical patent/AU2020258017A1/en
Application granted granted Critical
Publication of AU2020258017B2 publication Critical patent/AU2020258017B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/713—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
AU2020258017A 2019-04-18 2020-04-17 New pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling Active AU2020258017B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19170003 2019-04-18
EP19170003.8 2019-04-18
EP19188639.9 2019-07-26
EP19188639 2019-07-26
PCT/EP2020/060819 WO2020212553A1 (en) 2019-04-18 2020-04-17 New pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling

Publications (2)

Publication Number Publication Date
AU2020258017A1 AU2020258017A1 (en) 2021-07-01
AU2020258017B2 true AU2020258017B2 (en) 2025-05-29

Family

ID=70480222

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020258017A Active AU2020258017B2 (en) 2019-04-18 2020-04-17 New pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling

Country Status (10)

Country Link
US (1) US12318388B2 (cg-RX-API-DMAC7.html)
EP (1) EP3955929B1 (cg-RX-API-DMAC7.html)
JP (1) JP7588859B2 (cg-RX-API-DMAC7.html)
KR (1) KR102857084B1 (cg-RX-API-DMAC7.html)
CN (1) CN113329753B (cg-RX-API-DMAC7.html)
AU (1) AU2020258017B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012834A2 (cg-RX-API-DMAC7.html)
DK (1) DK3955929T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981773T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020212553A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3527571A1 (en) * 2018-02-14 2019-08-21 Université de Liège Pyrimidine derivatives for prevention and treatment of bacterial infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009034386A1 (en) * 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
WO2019158655A1 (en) * 2018-02-14 2019-08-22 Universite De Liege Pyrimidine derivatives for prevention and treatment of bacterial infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4928399A (en) * 1998-07-27 2000-02-21 M & M Laboratory Co., Ltd. Ion complex, coating material, and coating method
WO2004021979A2 (en) * 2002-09-06 2004-03-18 Smithkline Beecham Corporation PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
DE102005060690B4 (de) * 2005-12-15 2008-09-25 Capsulution Nanoscience Ag Salze von Clopidogrel mit Polyanionen und ihre Verwendung zur Herstellung pharmazeutischer Formulierungen
EP2236158A1 (en) * 2009-03-30 2010-10-06 Pharnext New therapeutic approaches for treating neuroinflammatory conditions
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
ES2731658T3 (es) 2016-09-09 2019-11-18 Univ Liege Derivados triazolo(4,5-d)pirimidina para uso en la prevención y tratamiento de infección bacteriana
GB201910656D0 (en) 2019-07-25 2019-09-11 Univ Liege New use of triazolo(4,5-d)Pyrimidine deerivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009034386A1 (en) * 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
WO2019158655A1 (en) * 2018-02-14 2019-08-22 Universite De Liege Pyrimidine derivatives for prevention and treatment of bacterial infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTTI VAARA: "Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics", MOLECULES ONLINE, vol. 24, no. 2, 11 January 2019 (2019-01-11), DE, pages 249, XP055629346, ISSN: 1433-1373, DOI: 10.3390/molecules24020249 *

Also Published As

Publication number Publication date
KR102857084B1 (ko) 2025-09-10
BR112021012834A2 (pt) 2021-09-28
JP7588859B2 (ja) 2024-11-25
DK3955929T3 (da) 2024-08-05
US20210290625A1 (en) 2021-09-23
WO2020212553A1 (en) 2020-10-22
AU2020258017A1 (en) 2021-07-01
KR20220003556A (ko) 2022-01-10
ES2981773T3 (es) 2024-10-10
JP2022529052A (ja) 2022-06-16
CN113329753A (zh) 2021-08-31
EP3955929B1 (en) 2024-05-15
US12318388B2 (en) 2025-06-03
CN113329753B (zh) 2024-08-13
CA3128304A1 (en) 2020-10-22
EP3955929A1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
AU2019220404B2 (en) Pyrimidine derivatives for prevention and treatment of bacterial infections
US20100267672A1 (en) Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
US20160000795A1 (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
TW200838540A (en) Sulfamoyl-containing derivatives and uses thereof
US20120238751A1 (en) Tricyclic gyrase inhibitors
WO2006095906A1 (ja) 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤
US20170217964A1 (en) Aminotetrahydropyran derivative used as dipeptidyl peptidaseiv inhibitor
US20170015672A1 (en) Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
US12318388B2 (en) Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling
JP2019502667A (ja) 抗菌化合物
CA3128304C (en) Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling
CA3090945C (en) Pyrimidine derivatives for prevention and treatment of bacterial infections
CZ2009359A3 (cs) Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující
US7615638B2 (en) Synthesis of grossularines-1 and analogs thereof and method of use
BR112020009290B1 (pt) Derivados de pirimidina, seu método de preparação e seu uso, composição farmacêutica, e método ex vivo para matar ou impedir o crescimento bacteriano na formação de biofilme
CA3102434A1 (en) Selective a2a receptor antagonist
WO2020255979A1 (ja) ピロロピリミジン骨格を有する新規なカーボネート化合物又はその薬学的に許容可能な塩
AU2010305416A1 (en) Pyrrolo [3,2 -e] [1,2,4] triazolo [1,5-a] pyrimidines derivatives as inhibitors of microglia activation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)